Search Results
Jan 12, 2026, 07:30 ET AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
- RC148 is a novel PD-1/VEGF bispecific antibody being evaluated in multiple advanced solid tumors including certain lung cancersNORTH CHICAGO, Ill. and YANTAI, China, Jan. 12, 2026 /PRNewswire/ -- AbbVie
More news about: AbbVie
Jan 12, 2026, 07:16 ET EQT Life Sciences backs Kinaset Therapeutics' USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases
Proceeds from the oversubscribed USD 103 million Series B round to help advance frevecitinib – a single-capsule dry powder inhaler delivering therapeutic lung concentrations, with the potential to treat the broad asthma populationEQT Life Sciences' Daniela Begolo to join Kinaset Therapeutics' Board
More news about: EQT
Jan 12, 2026, 07:00 ET CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the
More news about: Cytosorbents Corp
Jan 12, 2026, 06:30 ET Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones
Commercial launch in the U.S. of zidesamtinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 tyrosine kinase inhibitor (TKI), pending U.S. Food and Drug Administration (FDA) review;Submit
More news about: Nuvalent, Inc.
Jan 11, 2026, 12:00 ET IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
advance key combinations and to address multiple indications with high unmet need, including uveal melanoma, small cell lung cancer, neuroendocrine cancer, breast cancer, and MTAP-deleted lung, pancreatic, and urothelial cancers. In 2026, we plan to advance four registrational trials, including for IDE849,
More news about: IDEAYA Biosciences, Inc.
Jan 10, 2026, 10:00 ET RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer
reaction occurs, permanently discontinue RYBREVANT®.Interstitial Lung Disease/PneumonitisRYBREVANT FASPRO™ and RYBREVANT® can cause severe and fatal interstitial lung disease (ILD)/pneumonitis.RYBREVANT FASPRO™ with LAZCLUZE®
More news about: Johnson & Johnson
Jan 09, 2026, 10:00 ET Continued Zenocutuzumab Treatment Beyond Progression Shows Benefit in Patients with NRG1+ Pancreatic Cancer and Cholangiocarcinoma: New Results from the eNRGy Trial Presented at ASCO GI
for Grade 4 or life-threatening IRR or hypersensitivity/anaphylaxis reactions.Interstitial Lung Disease/PneumonitisBIZENGRI can cause serious and life-threatening interstitial lung disease (ILD)/pneumonitis.In the eNRGy study, ILD/pneumonitis occurred in 2 (1.1%) patients treated
More news about: Partner Therapeutics, Inc.
Jan 09, 2026, 08:02 ET iOnctura CEO to present at the 2026 J.P. Morgan Healthcare Conference
program in larger market indications.The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis began in November 2025.Logo :
More news about: iOnctura
Jan 09, 2026, 07:00 ET Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
avium complex (MAC) lung disease who have not started antibiotics.Pending successful results from the ENCORE trial, Insmed plans to submit a supplementary new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for ARIKAYCE in all patients with MAC lung disease in the U.S.
More news about: Insmed Incorporated
Jan 09, 2026, 02:00 ET Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology
its R&D pipeline. PFL-241 and PFL-721, two mutant-selective EGFR inhibitors, are being developed for the treatment of EGFR-driven non-small cell lung cancer (NSCLC) patients. PFL-002 is undergoing clinical testing in solid tumors driven by MET genetic alterations. The pan-RAF inhibitor exarafenib
More news about: Pierre Fabre Laboratories
Jan 09, 2026, 02:00 ET Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology
its R&D pipeline. PFL-241 and PFL-721, two mutant-selective EGFR inhibitors, are being developed for the treatment of EGFR-driven non-small cell lung cancer (NSCLC) patients. PFL-002 is undergoing clinical testing in solid tumors driven by MET genetic alterations. The pan-RAF inhibitor exarafenib
More news about: Pierre Fabre Laboratories
Jan 08, 2026, 19:00 ET MediLink Has Signed an Additional Exclusive Licensing Agreement with Roche
reflects Roche's commitment to leveraging cutting-edge innovation from around the globe to address unmet patient needs, particularly within oncology and lung cancer as one of our strategic priorities. We are excited to combine MediLink's and Roche's expertise in ADCs with our well established global development
More news about: MediLink Therapeutics
Jan 08, 2026, 11:25 ET FORMER NFL STARS TEAM UP WITH CDC TO TACKLE LUNG CANCER IN "GEAR UP AGAINST CANCER" CAMPAIGN
lung cancer is the third most common cancer in the United States — and the leading cause of cancer deaths for both men and women. In 2023 alone, 131,584 people died from lung cancer in the United States. Regular screenings for adults at high risk for developing lung cancer can detect
More news about: NFL Alumni
Jan 08, 2026, 11:00 ET DELFI Diagnostics Appoints Cindy Soriano as Chief Financial Officer and Announces Participation in 44th Annual J.P. Morgan Healthcare Conference
health issues, including in historically underserved demographics, and have the potential to save lives on a global scale. FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and requires a simple blood draw that can be incorporated with routine
More news about: DELFI Diagnostics
Jan 08, 2026, 11:00 ET SU2C DREAM TEAM TARGETS EARLY DETECTION OF GASTRIC CANCER
molecular imaging—may also help detect other digestive tract cancers, including esophageal, colon and pancreatic cancers. Some tools could even apply to lung cancer detection in the future.About Stand Up To CancerStand Up To Cancer® (SU2C) raises awareness and funds
More news about: Stand Up To Cancer
Jan 08, 2026, 08:00 ET Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
application for HWK-007, its PTK7-targeted ADC. Whitehawk's Phase 1 trial for HWK-007 is now actively recruiting and will initially evaluate activity in lung and ovarian cancers, two PTK7-expressing tumor types with established precedent data, as well as endometrial cancer, one of the highest PTK7-expressing
More news about: Whitehawk Therapeutics, Inc.
Jan 08, 2026, 07:30 ET Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced strategic updates ahead of its participation in the 15th Annual LifeSci Partners
More news about: Trevi Therapeutics, Inc.
Jan 08, 2026, 07:01 ET Adam Clermont Releases New Book - Profit Before People: When Corporations Knew It Was Dangerous and Sold It Anyway
defects from a 1960s sedative, defective contraceptives, fuel tank explosions in compact cars, ignition failures causing crashes, exploding airbags, lung disease from insulation materials, addictive painkillers, emissions deception, and widespread chemical contamination.The same sequence repeats:
More news about: Adam Clermont
Jan 08, 2026, 04:01 ET Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients was initiated in the second quarter of 2025. www.foreseepharma.com
More news about: Foresee Pharmaceuticals Co., Ltd.
Jan 08, 2026, 03:42 ET Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which the Phase 2 WINDWARD study in pulmonary hypertension-interstitial lung disease (PH-ILD) patients was initiated in the second quarter of 2025. www.foreseepharma.com
More news about: Foresee Pharmaceuticals Co., Ltd.
Jan 07, 2026, 20:00 ET Casio ra mắt đồng hồ MR-G với màu xanh hanada-iro truyền thống của Nhật Bản
Bản.Chiếc đồng hồ này lấy cảm hứng từ khung cảnh huyền ảo của một bảo vật quốc gia, ngôi chùa tháp năm tầng, thấp thoáng trong làn sương sớm lơ lửng tại tỉnh Yamagata, nơi các mẫu đồng hồ MR-G được sản xuất. Mặt số màu xanh biến đổi tinh tế về diện mạo theo ánh sáng và góc nhìn, gợi lên khoảnh khắc
More news about: CASIO COMPUTER CO., LTD
Jan 07, 2026, 14:01 ET Function Launches New App in ChatGPT
advanced MRI is designed to detect signs of cancers, unruptured aneurysms, endometriosis, stroke, and more, while the CT scan can search for signals of lung cancer, plaque in the heart, and other serious health conditions. Function is redefining what it means to take control of your health.
More news about: Function Health
Jan 07, 2026, 09:00 ET CSA Medical Submits PMA for RejuvenAir® System Following Positive Results from Pivotal SPRAY-CB Trial
destroying these damaged cells without creating scar tissue, the body can begin the rapid regrowth of new, healthy normal functioning cells in the lung. The RejuvenAir System is an investigational device and not currently commercially available in the United States.
More news about: CSA Medical
Jan 07, 2026, 08:33 ET Korea University Researchers Discover That Cholesterol-lowering Drug Can Overcome Chemotherapy Resistance in Triple-Negative Breast Cancer
significantly reduced organoid size and viability.In CSC-derived allograft mouse models, pitavastatin markedly reduced tumor growth, angiogenesis, and lung metastasis without inducing organ toxicity or causing significant body weight loss. Tumor sections showed a marked reduction in the proliferation marker
More news about: Korea University College of Medicine
Jan 07, 2026, 08:00 ET Remedy Cell Announces Initiation of Phase 1b Clinical Trial of RC-0315 in IPF Patients
pulmonary fibrosis (IPF) is a fatal, highly complex and progressive interstitial lung disease affecting approximately 3 million people worldwide. With a survival of only 2-5 years post-diagnosis, it is characterized by interstitial lung tissue becoming thick and stiff with an excessive buildup of collagen. The
More news about: Remedy Cell